0001104659-22-073980.txt : 20220623
0001104659-22-073980.hdr.sgml : 20220623
20220623184726
ACCESSION NUMBER: 0001104659-22-073980
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220621
FILED AS OF DATE: 20220623
DATE AS OF CHANGE: 20220623
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jovan-Embiricos Morana
CENTRAL INDEX KEY: 0001575745
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 221036612
MAIL ADDRESS:
STREET 1: C/O RADIUS HEALTH, INC.
STREET 2: 201 BROADWAY, 6TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: F2 Bioscience I 2017 Ltd
CENTRAL INDEX KEY: 0001838573
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 221036613
BUSINESS ADDRESS:
STREET 1: 8, RUE SAINT-LEGER
CITY: GENEVA
STATE: V8
ZIP: CH 1205
BUSINESS PHONE: 44-22-317-7842
MAIL ADDRESS:
STREET 1: 8, RUE SAINT-LEGER
CITY: GENEVA
STATE: V8
ZIP: CH 1205
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Oncology, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Management, Inc.
DATE OF NAME CHANGE: 20210107
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
tm2219298-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-06-21
0
0001789972
Cullinan Oncology, Inc.
CGEM
0001838573
F2 Bioscience I 2017 Ltd
C/O LJ MANAGEMENT (SUISSE) SA
8, RUE SAINT-LEGER
GENEVA
V8
CH-1205
SWITZERLAND
0
0
1
0
0001575745
Jovan-Embiricos Morana
C/O LJ MANAGEMENT (SUISSE) SA
8, RUE SAINT-LEGER
GENEVA
V8
CH-1205
SWITZERLAND
0
0
1
0
Common Stock
2022-06-21
4
S
0
22319
12.7662
D
616976
D
Common Stock
2022-06-22
4
S
0
49953
12.7035
D
567023
D
Common Stock
2022-06-23
4
S
0
29631
13.0036
D
537392
D
Common Stock
1136525
I
By Globeways Holdings Ltd.
Common Stock
1305873
I
F2 Vision SCS
Common Stock
325333
I
By F2 MG Ltd.
Common Stock
622175
I
By F2-TPO Investments, LLC
Common Stock
71599
I
By F2 Bio TD, LLC
Common Stock
214798
I
By F2 MC, LLC
Common Stock
104762
I
By F2 GC, LLC
Common Stock
112507
I
By Morana Jovan-Embiricos
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.58 to $12.99, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.35 to $12.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.72 to $13.35, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
These securities are owned directly by Globeways. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Dr. Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Rachel Higham /s/ Ivan Bedford, for F2 Bioscience I 2017 Limited
2022-06-23
/s/ Morana Jovan-Embiricos
2022-06-23